[1] Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development [J]. Arch Neurol, 2003, 60(4): 496-500.
[2] Cooper EC, Aldape KD, Abosch A, et al. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy [J]. Proc Nati Acad Sci U S A, 2000, 97(9): 4914-4919.
[3] US FDA. FDA approves Potiga to treat seizures in adults [EB/OL]. [2011-06-13].
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 258834.htm
[4] Lankau HJ, Unverferth K, Arnold T, et al. Process for the production of 1,2,4-triaminobenzene carbamic acid esters: US, 20030023111 [P]. 2003-01-30.
[5] 左 莉. 依佐加滨( ezogabine) [ J] . 中国药物化学杂志, 2011, 21(6): 505-506.
[6] Dieter HR, Engel J, Kutscher B, et al. Pharmaceutically active 1,2,4-triamino-benzene derivatives，processes for their preparation and pharmaceutical compositions containing: US, 5384330 [P]. 1993-01-08.
[7] Va s a n t h a B, Hema n t h a HP, S u r e s h b a b u VV. 1 -Propanephosphonic acid cyclic anhydride (T3P) as an efficient promoter for the Lossen rearrangement: application to the synthesis of urea and carbamate derivatives [J] . Synthesis, 2010, 17: 2990-2996.
[8] Mario R, Andreas R. 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system: US, 20060014822 [P]. 2006-01-19.
[9] Antonio G, Laurence G, Amelie L, et al. Quinazoline-urea, new protein kinase Inhibitors in treatment of prostate cancer [J]. J Enzyme Inhib Med Chem, 2010, 25(2): 158-171.
[10] Sobanov AA, Zolotukhin AV, Galkina IV, et al. Kinetics and mechanism of the Pudovik reaction in the azomethine series: Ⅲ . Acid-catalyzed hydrophosphorylation of imines [J]. Russ J Gen Chem, 2006, 76(3): 421-429.
[11] Serra MJ, Duran LE, Boschillado J. Diethyl 4-( 4-fluorobenzylamino)-1,2-phenylenedicarbamate, and salts thereof: WO, 2011012659 [P]. 2011-02-03.
基金
国家“973”计划(2007CB512102)、国家自然科学基金重点项目(30730031)
{{custom_fund}}
